Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* A diagnosis of allergic asthma, uncontrolled on current medication.~* History of at least 2 asthma exacerbations during the last 1 year~* Forced Expiratory Volume in one second (FEV1) of ≥ 40% and ≤ 80% of the predicted normal value; reversibility following administration of bronchodilator.~Key Exclusion Criteria:~* Use of tobacco products within the previous 6 months (Social occasional smokers may be included).~* Recent asthma attack/exacerbation or asthma worsening/ respiratory infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- QGE031 240 mg (Type: EXPERIMENTAL): QGE031 240 mg subcutaneous injection every 4 weeks
- QGE031 72 mg (Type: EXPERIMENTAL): QGE031 72 mg subcutaneous injection every 4 weeks
- QGE031 24 mg (Type: EXPERIMENTAL): QGE031 24 mg subcutaneous injection every 4 weeks
- Placebo to QGE031 (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).